Kanoria Chemicals & Industries Ltd. Overview
Kanoria Chemicals & Industries is a 65-year-old, promoter-controlled Indian manufacturer of formaldehyde-chain "Alco Chemicals": formaldehyde, pentaerythritol (Penta/PE), hexamine, sodium formate, phenolic resins and acetaldehyde. It runs three plants at Ankleshwar (Gujarat), Visakhapatnam and Naidupeta (Andhra Pradesh), with combined formaldehyde capacity of about 1,400 tonnes per day (TPD). The products go mainly into construction, infrastructure, paints and coatings, plywood/laminates, pharmaceuticals and agrochemicals. The company says it leads the Indian market in most of its products, and it is the petitioner behind India's pentaerythritol anti-dumping duties. Through its wholly owned Ethiopian subsidiary, Kanoria Africa Textiles PLC, it also makes integrated denim. In July 2025 it exited a loss-making European automotive-electronics subsidiary (APAG), and it is now repositioning as a focused chemicals company under a "Vision-2030" plan. That plan centres on specialty derivatives (Triacetin, Penta derivatives), resin and formaldehyde capacity, and renewable-energy-led cost reduction. The company is small-cap (about ₹800 Cr market value), BB+-rated, and moderately leveraged.
What the company does
KCIL makes commodity and semi-specialty chemical intermediates on a methanol-to-formaldehyde chain. Methanol (bought in) is oxidised to formaldehyde. Formaldehyde is either sold to resin, plywood/laminate and chemical customers, or used captively to make:
- Pentaerythritol (PE / "Penta"), a polyol for alkyd resins in paints and coatings, plus inks, lubricants and explosives intermediates. Sodium formate is a co-product of the Penta process.
Hexamine: (hexamethylenetetramine), used in rubber curing, phenolic moulding compounds, pharmaceuticals and fuel tablets. A significant share is exported to Europe and the USA.
-
Phenolic resins, from phenol plus formaldehyde, for foundry, friction, laminates and abrasives.
-
Acetaldehyde, listed in the FY25 MD&A product portfolio.
The FY25 MD&A says Penta, hexamine and phenolic-resin process technologies were developed in-house and refined over time for global cost and quality competitiveness. It also says the formaldehyde plants use modern technology that gives cost and quality advantages.
The second continuing business is Textiles: an integrated denim mill in Ethiopia run through Kanoria Africa Textiles PLC (KAT), a wholly owned subsidiary.
The third, now discontinued, business was Electronics/Automotive. APAG Holding AG (Switzerland) and its subsidiaries in Switzerland, the Czech Republic, Germany (CoSyst Control Systems GmbH) and North America designed and manufactured electronic control units and mechatronic modules for automotive and industrial OEMs. APAG ceased to be a subsidiary with effect from 31 July 2025 and is reported under discontinued operations in FY26.
A fourth small activity, a 5 MW solar power plant at Village Bap, Jodhpur (Rajasthan), was sold on a slump-sale basis in FY25 (approved 3 May 2024; buyer SML Electricals India; consideration about ₹8.2 Cr per Reuters).
Company's own description (paraphrased from the FY25 MD&A)
Management describes the Alco Chemicals Division as serving construction, infrastructure, paints, pharma and agrochemicals. Its portfolio is formaldehyde, pentaerythritol, hexamine, sodium formate, phenolic resins and acetaldehyde, made at Ankleshwar, Vizag and Naidupeta. Management claims market leadership in most of these products and a significant presence in the rest. Screener's business summary, drawn from company documents, describes KCI as a maker of chemical intermediates and specialities focused on infrastructure and construction.
Business and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model | Almost entirely product sales (B2B bulk/semi-bulk chemicals; denim fabric). No meaningful service, subscription or licensing revenue disclosed |
| Pricing | Spot and contract pricing linked to methanol and phenol costs. Margins are spread-driven (product price minus methanol/phenol cost) and exposed to import parity and anti-dumping protection |
| Value-chain position | Mid-stream. Buys methanol and phenol (largely import-linked, crude/gas-correlated); sells intermediates to downstream formulators |
| Customer types | Paint and coatings makers (Penta), plywood/laminate and resin makers (formaldehyde), foundry and friction-material makers (phenolic resins), rubber and pharma (hexamine), chemical traders. FY23 BRSR lists paint, plywood, chemicals and foundry customers |
| End-markets | Construction and real estate, infrastructure, paints, wood panels/furniture, automotive (friction, rubber), pharma, agrochemicals; garment/denim (Ethiopia) |
| Capital intensity | Moderate. Standalone net fixed assets about ₹438 Cr against FY26 revenue of ₹875 Cr |
| Geographic model | Mainly domestic India sales, plus hexamine exports to Europe and the USA (FY26 Directors' Report) and Ethiopian domestic denim sales |
Independent characterisation
After the APAG exit, KCIL is a single-chain, India-centric formaldehyde derivatives producer with a small African textile appendage. It is cyclical and spread-based. Earnings swing with three things: (a) methanol and phenol prices against Indian demand, (b) the intensity of Chinese, Middle Eastern and Russian dumping, which management cites repeatedly, and (c) trade-remedy protection (Penta anti-dumping duty imposed May 2024). The economics improved in FY26 for four reasons:
-
The loss-making APAG was removed. It had an EBITDA loss of ₹6.6 Cr and a net loss of ₹54.6 Cr in FY25.
-
345 TPD of new formaldehyde and 18 TPD of new hexamine capacity at Ankleshwar became operational (September 2024).
-
The Penta anti-dumping duty took effect.
-
Ethiopia recovered.
Q1FY27 standalone revenue of about ₹430 Cr, roughly half of the whole of FY26 standalone revenue (₹875 Cr), implies a step change. The sources reviewed do not explain it, so the durability of this run-rate is the central analytical question.
Strategy
Stated strategy: "Vision-2030"
The FY25 MD&A describes Vision-2030 as a long-term plan covering new product lines and expansion of the existing portfolio. Its stated aim is substantial growth in revenue and profitability by 2030. The FY26 Directors' Report and the September 2026 AGM presentation restate the themes:
-
Specialty diversification: Triacetin and Penta derivatives / multi-purpose specialty plant, in advanced construction and "expected to be commissioned shortly".
-
Core capacity: further formaldehyde and phenolic-resin capacity. Resin expansion is under construction; formaldehyde addition is being "actively pursued".
-
R&D and new product development (NPD): a dedicated NPD cell, with the R&D team and infrastructure "significantly augmented" in FY26. Focus areas are new applications, waste elimination and "waste-to-wealth".
-
Cost reduction: renewable power (about 80% of Ankleshwar), energy-efficiency projects (Penta steam optimisation, hydro turbine, IRIS monitoring, 66 kV grid), supply-chain strengthening.
-
Portfolio focus: exit from non-core and loss-making businesses (solar FY25; APAG FY26); targeted reinvestment in KAT (weaving expansion).
-
Funding: promoter support via ₹49.5 Cr of 7% NCRPS for capex, working capital and general corporate purposes.
Initiatives in the last 24 months (Oct 2024–Oct 2026)
| Initiative | Date | Status / target |
|---|---|---|
| 345 TPD formaldehyde + 18 TPD hexamine at Ankleshwar | Commissioned Sep 2024 | Operating; formaldehyde 1,400 TPD, hexamine 52 TPD |
| Triacetin plant | Construction started FY25; advanced FY26 | Commissioning "shortly" (Sep 2026) |
| Multi-purpose plant (Penta derivatives, specialties) | Construction started FY25 | Commissioning "shortly" |
| Phenolic resin capacity additions | One tranche commissioned FY26; further tranche under construction | Capacity not disclosed |
| Group-captive hybrid wind-solar power at Ankleshwar | Adopted FY26 | About 80% of unit's power; similar project under discussion at Vizag |
| Phenol Recovery Plant | Stabilised at Ankleshwar; under implementation at Vizag | — |
| Ion-exchange treatment of hexamine waste stream | Commissioned at Ankleshwar and Vizag | — |
| Carbon footprint assessment | FY26 | Company claims one of the lowest emission intensities among comparable producers (self-reported) |
| APAG divestment | Approved 29 Jul 2025; effective 31 Jul 2025 | Tranche 2 (14.3%) in FY2029-30 |
| KAT weaving expansion | Under board evaluation | "Moderate" capex |
| NCRPS ₹49.5 Cr | Allotted 18 Apr 2026 | Funds capex/working capital |
Medium-term financial targets / guidance
No quantified revenue, margin or return targets have been published in the sources reviewed. Vision-2030 is qualitative ("substantial revenue and profitability growth by 2030"). No earnings calls or investor days are held or transcribed.
Products & Services
Chemicals segment (continuing)
| Product | Description and applications | Capacity / plant | Target customers | Notes |
|---|---|---|---|---|
| Formaldehyde (aqueous, typically 37%) | C1 building block from methanol oxidation; used for urea-, melamine- and phenol-formaldehyde resins and as captive feed for Penta, hexamine and phenolic resins | About 1,400 TPD total across Ankleshwar, Visakhapatnam and Naidupeta, after the 345 TPD Ankleshwar plant (Sep 2024) | Plywood/laminate/MDF makers, resin producers, chemical manufacturers | FY23 BRSR lists formaldehyde as the largest product at about 51% of turnover. Further formaldehyde capacity is under evaluation (Vision 2030) |
| Pentaerythritol (Penta / PE) | Polyol for alkyd resins (paints/coatings), rosin esters (inks), synthetic lubricants, PETN | Ankleshwar (capacity not disclosed in sources reviewed) | Paint and coatings majors, ink and resin makers | KCIL and Asian Paints are described as India's two major Penta producers. Protected by anti-dumping duty since 16 May 2024. Process developed in-house |
| Sodium formate | Co-product of Penta; used in leather tanning, textile dyeing, de-icing, drilling fluids | Ankleshwar | Leather, textile and oilfield chemicals users | Management flags cheaper imports as a threat |
| Hexamine | Hexamethylenetetramine; rubber vulcanisation accelerator, phenolic moulding curing agent, pharma (methenamine), fuel tablets | 52 TPD total after the 18 TPD Ankleshwar addition (Sep 2024); also produced at Vizag (Ion Exchange waste treatment at both) | Rubber/tyre, phenolic moulders, pharma, exporters | Large export share to Europe and the USA. FY26 exports hurt by weak European demand and high US tariffs |
| Phenolic resins | Phenol-formaldehyde resins (novolac/resol) for foundry, friction, abrasives, laminates | Visakhapatnam: originally 3,000 MTPA automated plant. Additional capacity commissioned in FY26 and a further expansion under construction (amounts not disclosed) | Foundry, brake-lining/friction, abrasives, laminate makers | Phenol Recovery Plant stabilised at Ankleshwar; similar unit being built at Vizag |
| Acetaldehyde | Intermediate for acetic acid, pyridines, Penta | Plant location not specified in sources | Chemical/pharma intermediates makers | Listed in FY25 MD&A portfolio |
| Triacetin (pipeline) | Glycerol triacetate; plasticiser for cigarette filters, food/pharma excipient, foundry sand hardener | New plant in advanced construction (FY26 Directors' Report); "expected to be commissioned shortly" (AGM, Sep 2026) | Tobacco filter, food, pharma, foundry customers | Vision-2030 diversification product from the NPD cell |
| Penta derivatives and specialty chemicals (pipeline) | Multi-purpose plant for Pentaerythritol derivatives (e.g., Penta esters; specific products not disclosed) and other specialties | Multi-purpose plant in advanced construction | Lubricants, coatings, specialty polymer customers | Vision-2030 |
Pricing model: no list prices are disclosed. Pricing is market/contract based and tracks methanol and phenol costs, so margins are spread-driven.
Textiles segment (continuing)
| Offering | Description | Capacity data | Customers |
|---|---|---|---|
| Denim fabric (integrated spinning–weaving–processing) | Integrated denim manufacturing in Ethiopia via KAT | Capacity utilisation 66% FY26 (56% FY25). Board evaluating extra weaving capacity at moderate capex, given surplus capacity in other departments | Ethiopian garment makers/domestic market; exports viable after devaluation (management view) |
Discontinued portfolios (for reference)
| Former offering | Description | Exit |
|---|---|---|
| APAG/CoSyst electronic control units, mechatronic modules, automotive and industrial electronics; ECU R&D and engineering services | Contract design and manufacture for Western automotive and industrial OEMs (ICE and EV platforms) | Deconsolidated 31 Jul 2025; about 14.3% residual stake |
| Solar power (5 MW PV, Jodhpur, REC scheme) | Merchant/REC-linked power generation since 2012 | Sold FY25 (about ₹8.2 Cr) |
| Chloro chemicals (caustic soda, chlorine, chlorinated paraffin, poly aluminium chloride, water-treatment chemicals, lindane, aluminium chloride) and captive coal power (2 × 25 MW) at Renukoot | Former integrated chlor-alkali complex | Sold to Aditya Birla Chemicals, 2011 |
| Industrial alcohol (15 million litres p.a., 1994) | Alcohol-based intermediates | — |
Financial Narrative
Basis:
-
Consolidated figures for FY22–FY25 include APAG.
-
FY26 is continuing operations only; APAG sits in discontinued operations, and FY25 is restated to ₹754.3 Cr in the FY26 report.
-
Primary series: Screener.in consolidated and standalone (from audited annual reports), cross-checked against Anand Rathi, the FY25 MD&A and the FY26 Directors' Report.
-
All figures in INR crore unless stated.
Consolidated income statement
Notes:
Owners' profit: It is derived as EPS × about 4.37 crore shares. FY25 owners' loss of ₹83.6 Cr matches the Fyers/Simply Wall St EPS of -19.13 to -19.34 (Simply Wall St reports net loss of ₹84.5 Cr and EPS of -19.34, a small discrepancy). FY26 owners' profit of ₹120.8 Cr matches MarketsMojo and Fyers. The total profit of ₹113.2 Cr includes the non-controlling interest's share of APAG's pre-disposal losses.
FY26 other income: of ₹103 Cr includes the ₹97.65 Cr gain on loss of control of APAG (discontinued operations). The FY25 figure is negative because of the ₹29.4 Cr goodwill impairment and other exceptional items.
FY26 tax: includes a ₹21.43 Cr deferred-tax remeasurement credit from adopting the new tax regime (Section 200, Income Tax Act 2025).
Gross profit: is not disclosed in sources reviewed. Aggregator gross-margin series (e.g., TipRanks) are internally inconsistent and are not used.
Revenue CAGR:
-
Consolidated FY22–FY25 (like-for-like, including APAG): about 3.9%.
-
Consolidated FY22–FY26 as reported: about -8% (distorted by the APAG deconsolidation).
-
Standalone FY21–FY26: about 17.7% (Screener: 18% 5-year).
-
Standalone FY22–FY26: about 7.8%.
Standalone income statement (the continuing chemicals business)
Notes:
-
FY24–FY26 EBITDA, pre-exceptional profit and exceptional items are from the FY25 MD&A and FY26 Directors' Report (₹ million converted).
-
FY22–FY23 EBITDA is Screener operating profit plus other income, so it is only approximately comparable.
-
FY26 exceptional item: ₹10.64 Cr impairment of the APAG investment.
-
FY25 exceptional items: ₹44.99 Cr impairment of foreign subsidiaries.
-
FY26 standalone tax was a credit of ₹5.74 Cr.
Balance sheet
Not disclosed in sources reviewed:
Cash and short/long-term debt split: Cash appears small: TipRanks gives a consolidated cash ratio of about 0.02. Net debt is therefore approximated as gross borrowings.
Working capital: Screener working-capital days are 17, 8, 9, -4 and -14 (FY22–FY26, consolidated); a negative figure implies payables and other current liabilities exceed receivables plus inventory.
Current ratio: (standalone, MD&A): 1.14 (FY24), 0.93 (FY25). FY26 not disclosed.
Contingent liabilities: about ₹178 Cr (Screener, latest).
Post-balance-sheet: ₹49.5 Cr of 7% NCRPS was issued in April 2026. Under Ind AS this is likely classified as a financial liability; Q1FY27 standalone other income included a ₹6.30 Cr fair-valuation gain on the NCRPS (aggregators state ₹63.0 crore, a lakh/crore error).
Cash flow
Notes:
-
The FY23 "dividends paid" figure is the derived cash outflow for the FY22 dividend of about ₹1 per share × 4.37 crore shares (timing assumed).
-
No buybacks have been authorised or executed in the period.
Ratios
Notes:
-
Ratios are computed from the tables above.
-
ROIC is not separately disclosed; ROCE is used as a proxy.
-
FY26 ROE and ROA are inflated by the ₹97.65 Cr one-off gain. Excluding it and the ₹21.4 Cr deferred-tax credit, FY26 adjusted owners' profit is roughly ₹1–2 Cr on a continuing basis. That is consistent with the Anand Rathi continuing PAT of ₹32.4 Cr less the deferred-tax credit and exceptional reversal; derived, approximate.
-
The standalone MD&A interest-coverage ratio is 2.92x (FY24) and 3.65x (FY25).
Commentary on trends, inflections and drivers
FY22 (peak of the pre-crisis cycle). Standalone operating margin hit 9% on post-COVID restocking and strong formaldehyde/Penta spreads. Standalone profit was ₹25 Cr and a dividend was paid. On a consolidated basis, APAG's thin margins (consolidated operating margin about 5%) and Ethiopia's foreign-currency shortages limited group profit to ₹2.2 Cr.
FY23–FY24 (spread compression). Standalone operating margin collapsed to 3% and then 1%. Management attributes this to a global surplus of basic chemicals, Chinese/Middle-Eastern/Russian dumping and weak demand in the second half of the year. Consolidated losses widened as APAG (FY24 net loss ₹37.5 Cr) and KAT (₹16.6 Cr) bled. Debt stayed at about ₹510 Cr, and interest coverage fell below 2x.
FY25 (operational recovery in India, structural crisis abroad). Standalone revenue rose 18% and EBITDA 69% to ₹53.6 Cr, helped by:
-
the Penta anti-dumping duty (May 2024);
-
the new Ankleshwar capacity (September 2024), despite the roughly three-week GPCB closure (20 September–10 October 2024).
However, ₹45 Cr of standalone impairments and a ₹29.4 Cr consolidated goodwill write-off on APAG, plus APAG's EBITDA turning negative (customers insourcing programmes, OEM price-downs, ECU R&D under-utilisation) and KAT's Birr-devaluation loss, produced a consolidated net loss of ₹108 Cr. Consolidated debt to EBITDA exceeded 14x; this is the trough of balance-sheet stress.
FY26 (portfolio surgery and turnaround).
-
APAG was deconsolidated. The ₹97.65 Cr gain on loss of control dominates reported profit; no cash consideration was received in tranche 1.
-
Consolidated borrowings halved from ₹595 Cr to ₹291 Cr, mainly because APAG's debt left the balance sheet.
-
Standalone revenue grew 29% to ₹875 Cr and EBITDA 52% to ₹81.6 Cr, a 9.3% margin. Management credits cost optimisation, R&D-driven process and product innovation, and supply-chain strengthening. It names headwinds: dumping, raw-material volatility, and weaker hexamine exports to Europe (demand) and the USA (tariffs).
-
KAT's turnaround (EBITDA ₹19.25 Cr) added a second profit stream.
Q1FY27 (inflection, partly unexplained).
-
Consolidated revenue ₹460.4 Cr, up 129% YoY and 51% QoQ.
-
EBITDA ₹51.8 Cr (+177% YoY), net profit ₹26.4 Cr.
-
Standalone revenue ₹430.0 Cr (+130% YoY), standalone net profit ₹26.4 Cr. This includes the ₹6.3 Cr NCRPS fair-value gain within ₹9.0 Cr of other income.
-
The consolidated quarterly revenue path is ₹201 Cr (Q1FY26), ₹210 Cr (Q2), ₹266 Cr (Q3), ₹304 Cr (Q4), ₹460 Cr (Q1FY27).
The filings and summaries reviewed do not explain the scale of the jump. A doubling of revenue on a broadly unchanged capacity base (1,400 TPD formaldehyde; new specialty plants not yet commissioned per the AGM) points to a large realisation or price effect, plausibly methanol-linked pass-through, together with volume gains. Margin (EBITDA margin 11.2% consolidated; chemicals segment result margin 9.3%) improved only modestly, which is consistent with a price-led rather than spread-led expansion.
Data conflict on Q1FY26 standalone loss: one summary gives ₹7.67 Cr (ScanX, August 2025) and another ₹4.67 Cr (Q1FY27 comparative per Multibagg/ScanX). The latter is probably the restated comparative.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Relationship | Activity | Status |
|---|---|---|---|---|
Kanoria Chemicals & Industries Ltd | India | Parent | Alco Chemicals (3 plants) | Active |
Kanoria Africa Textiles PLC (KAT) | Ethiopia | 100% subsidiary (per FY26 Directors' Report) | Integrated denim | Active. A January 2025 board approval to dispose of 8,684,325 shares (13.79%) was disclosed; the FY26 report still calls KAT wholly owned, so completion is not confirmed |
APAG Holding AG | Switzerland | Former subsidiary (55% before dilution); about 14.3% residual stake after first tranche | Automotive/industrial electronics holding | Deconsolidated w.e.f. 31 Jul 2025 |
APAG Elektronik AG; APAG Elektronik s.r.o.; CoSyst Control Systems GmbH; APAG Elektronik LLC; APAG Elektronik Corp.; Adapt Control Systems GmbH; Adapt Control Systems Inc. | Switzerland, Czech Republic, Germany, North America, Canada | Former step-down subsidiaries | ECU/mechatronics design and manufacture | Deconsolidated with APAG |
Segment / entity revenue (INR Cr)
| Segment / entity revenue (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Chemicals (standalone revenue from operations) | 576.9 | 678.3 | 875.3 |
Textiles (KAT revenue from operations) | 108.1 | 76.0 | 106.1 |
Electronics/Automotive (APAG revenue from operations) | 790.1 | 782.4 | 0 |
Consolidated revenue as reported | 1,475 | 1,537 | 981 |
Segment EBITDA (INR Cr)
| Segment EBITDA (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Chemicals (standalone EBITDA incl. other income, before exceptional items) | 31.7 | 53.6 | 81.6 |
Electronics/Automotive (APAG EBITDA) | 27.7 | -6.6 | 0 |
Segment net profit (INR Cr)
| Segment net profit (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
APAG net loss | -37.5 | -54.6 | 0 |
KAT net loss | -16.6 | -31.2 | 0 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 1,369 | 1,578 | 1,475 | 1,537 | 981 |
Operating profit before other income (INR Cr) | 68 | 72 | 52 | 31 | 71 |
Other income (INR Cr) | 29 | 10 | 16 | -19 | 103 |
EBITDA as reported by Anand Rathi (INR Cr) | 97.0 | 82.7 | 72.0 | 40.6 | 93.8 |
Finance costs (INR Cr) | 27 | 36 | 43 | 46 | 32 |
Depreciation (INR Cr) | 57 | 59 | 59 | 63 | 35 |
Profit before tax incl. discontinued gain (INR Cr) | 13 | -12 | -34 | -96 | 107 |
Profit before tax, continuing ops, Anand Rathi (INR Cr) | 13.1 | -12.2 | -36.0 | -97.3 | 26.6 |
Net profit, total (INR Cr) | 2.2 | -12.9 | -55.3 | -108.2 | 113.2 |
Net profit attributable to owners (INR Cr) | 6.8 | -8.8 | -38.4 | -83.6 | 120.8 |
EPS basic, owners (INR) | 1.56 | -2.01 | -8.79 | -19.13 | 27.64 |
EPS diluted (INR) | 1.56 | -2.01 | -8.79 | -19.13 | 27.64 |
Dividend per share (INR) | 1.0 | 0 | 0 | 0 | 0 |
Margin metric (%)
| Margin metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating margin before other income (%) | 5.0 | 4.6 | 3.5 | 2.0 | 7.2 |
EBITDA margin, Anand Rathi basis (%) | 7.1 | 5.2 | 4.9 | 2.6 | 9.6 |
Net margin, total profit (%) | 0.2 | -0.8 | -3.7 | -7.0 | 11.5 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 649 | 675 | 577 | 678 | 875 |
Operating profit before other income (INR Cr) | 59 | 19 | 6 | 39 | 55 |
Operating margin (%) | 9 | 3 | 1 | 6 | 6 |
EBITDA incl. other income, before exceptional items (INR Cr) | 70 | 40 | 31.7 | 53.6 | 81.6 |
Finance costs (INR Cr) | 9 | 10 | 12 | 16 | 19 |
Depreciation (INR Cr) | 21 | 21 | 18 | 20 | 23 |
Profit before exceptional items and tax (INR Cr) | 40 | 9 | 2 | 17.5 | 39.3 |
Exceptional items (INR Cr) | 0 | 0 | 0 | -45.0 | -10.6 |
Net profit (INR Cr) | 25 | 6 | -1 | -38 | 34.4 |
EPS basic (INR) | 5.72 | 1.36 | -0.25 | -8.69 | 7.88 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Financial Ratios (x)
| Consolidated balance sheet (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital | 22 | 22 | 22 | 22 | 22 |
Reserves | 577 | 584 | 579 | 499 | 551 |
Total equity (excl. NCI where shown) | 599 | 606 | 601 | 521 | 573 |
Borrowings (total debt) | 475 | 510 | 509 | 595 | 291 |
Other liabilities | 329 | 366 | 380 | 382 | 253 |
Total liabilities and equity | 1,403 | 1,481 | 1,490 | 1,498 | 1,117 |
Net fixed assets | 863 | 882 | 850 | 865 | 727 |
Capital work in progress | 10 | 10 | 47 | 46 | 32 |
Investments | 22 | 17 | 16 | 14 | 59 |
Other assets (incl. working capital, cash) | 507 | 573 | 578 | 574 | 299 |
Debt to equity (x) | 0.79 | 0.84 | 0.85 | 1.14 | 0.51 |
Balance Sheet and Financial Ratios (x) by Standalone Balance Sheet
| Standalone balance sheet (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total equity | 639 | 641 | 639 | 601 | 638 |
Borrowings | 97 | 124 | 143 | 197 | 183 |
Net fixed assets | 400 | 405 | 380 | 423 | 438 |
Capital work in progress | 5 | 0 | 32 | 14 | 26 |
Investments | 209 | 218 | 210 | 163 | 183 |
Total assets | 901 | 907 | 944 | 986 | 1,051 |
Debt to equity (x) | 0.15 | 0.19 | 0.22 | 0.33 | 0.29 |
Consolidated cash flow (INR Cr)
| Consolidated cash flow (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 83 | 26 | 38 | 15 | 71 |
Investing cash flow | -43 | -29 | -50 | -59 | -8 |
Financing cash flow | -53 | 3 | 5 | 41 | -58 |
Capital expenditure (derived CFO minus FCF) | 42 | 38 | 75 | 79 | 51 |
Free cash flow | 41 | -12 | -37 | -64 | 20 |
Dividends paid (derived) | 0 | 4.4 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Standalone cash flow (INR Cr)
| Standalone cash flow (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 49 | 25 | 26 | 11 | 74 |
Capital expenditure (derived) | 12 | 12 | 32 | 33 | 44 |
Free cash flow | 37 | 13 | -6 | -22 | 30 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE consolidated, owners' profit ÷ closing equity (%) | 1.1 | -1.5 | -6.4 | -16.0 | 21.1 |
ROA consolidated, total profit ÷ total assets (%) | 0.2 | -0.9 | -3.7 | -7.2 | 10.1 |
ROCE consolidated, Screener (%) | 4 | 1 | 1 | -2 | 6 |
ROCE standalone, Screener (%) | 7 | 1 | 1 | 4 | 7 |
Debt to equity consolidated (x) | 0.79 | 0.84 | 0.85 | 1.14 | 0.51 |
Gross debt to EBITDA consolidated (x) | 4.9 | 6.2 | 7.1 | 14.7 | 3.1 |
Interest coverage, EBITDA ÷ finance cost (x) | 3.6 | 2.3 | 1.7 | 0.9 | 2.9 |
Asset turnover consolidated (x) | 0.98 | 1.07 | 0.99 | 1.03 | 0.88 |
Cash conversion cycle consolidated (days) | 63 | 61 | 68 | 63 | 34 |
Cash conversion cycle standalone (days) | 38 | 40 | 29 | 42 | 28 |
Debtor days consolidated | 46 | 45 | 46 | 56 | 50 |
Inventory days consolidated | 97 | 91 | 104 | 84 | 55 |
Payable days consolidated | 80 | 75 | 82 | 78 | 70 |
Region (operating-entity proxy) revenue (INR Cr)
| Region (operating-entity proxy) revenue (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India (standalone chemicals) | 576.9 | 678.3 | 875.3 |
Africa (Ethiopia, KAT) | 108.1 | 76.0 | 106.1 |
Europe and North America (APAG) | 790.1 | 782.4 | 0 |
Region growth YoY (%)
| Region growth YoY (%) | FY2025 | FY2026 |
|---|---|---|
India (standalone chemicals) | 17.6 | 29.0 |
Africa (Ethiopia, KAT) | -29.7 | 39.6 |
Europe and North America (APAG) | -1.0 | -100 |
Capital Markets
| Item | Value | Source / date |
|---|---|---|
Last price | ₹182.10 | ScanX / IIFL, 6 Oct 2026 close |
Market capitalisation | ₹795.66 Cr | ScanX |
Recent prices | ₹199.62 (29 Sep 2026); ₹198.77 (30 Sep 2026); ₹149.69 (7 Aug 2026); ₹121 (late May 2026) | IIFL; Screener |
52-week low | about ₹55.7 (Screener range; date within the last 12 months, not exact) | Screener |
1-year return | +127.7% | ScanX |
6-month return | +183.3% | ScanX |
5-year return | -14.6% | ScanX |
Share price performance (%) | 1Y | 5Y |
KANORICHEM total price return (%) | 127.7 | -14.6 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E (TTM, reported) | about 5.0x (ScanX: 5.21x) | TTM owners' profit about ₹160 Cr including APAG gain and deferred-tax credit |
P/E (TTM, ex one-offs, rough) | about 20–25x | Excludes ₹97.65 Cr gain, ₹21.4 Cr deferred-tax credit, ₹6.3 Cr NCRPS gain; derived |
P/B | about 1.4x | Consolidated book value about ₹131/share (Mar 2026) |
EV | about ₹1,136 Cr | Market cap ₹796 Cr + borrowings ₹291 Cr (Mar 2026) + NCRPS ₹49.5 Cr; cash assumed negligible |
EV/EBITDA (FY26) | about 12.1x | EBITDA ₹93.8 Cr |
EV/EBITDA (TTM to Q1FY27) | about 9.0x | TTM EBITDA about ₹126.9 Cr (FY26 − Q1FY26 ₹18.7 Cr + Q1FY27 ₹51.8 Cr) |
EV/Sales (TTM) | about 0.92x | TTM revenue about ₹1,240 Cr |
Dividend per share (INR)
| Dividend per share (INR) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
DPS (INR) | 0 | 1.0 | 0 | 0 | 0 | 0 |
Credit Ratings
| Agency | Rating | Outlook |
|---|---|---|
CARE Ratings: long-term bank facilities | CARE BB+ | Stable |
CARE Ratings: short-term bank facilities | CARE A4+ | — |
Moody's / S&P / Fitch | Not rated | — |
Analyst Conclusions
Management guidance
Quantitative guidance: none.
Qualitative (AGM, September 2026; FY26 Directors' Report): - Triacetin and Penta-derivative plants to be commissioned "shortly".
-
Formaldehyde and resin capacity additions being pursued.
-
Cost-reduction programmes continuing.
-
KAT sales momentum expected to sustain, with weaving expansion under evaluation.
-
Geopolitics and high tariffs flagged as headwinds.
-
Demand outlook tied to Indian GDP growth.
Consensus
No consensus estimates exist (no sell-side coverage).
Bull case
-
Run-rate re-basing. Q1FY27 consolidated revenue of ₹460 Cr and EBITDA of ₹51.8 Cr annualise to about ₹1,800 Cr and about ₹200 Cr, against an EV of about ₹1,136 Cr. Even a partial hold would put the stock on about 6x forward EV/EBITDA.
-
Mix upgrade. Triacetin and Penta derivatives add higher-margin specialty revenue on top of a captive formaldehyde base, with anti-dumping protection on Penta until about 2029.
-
Balance-sheet and governance clean-up. Exiting APAG halved debt (₹595 Cr to ₹291 Cr), removed a business losing about ₹55 Cr a year, and the promoter injected ₹49.5 Cr. A CARE upgrade from BB+ could follow sustained profitability.
Bear case
-
Earnings quality. FY26 profit is about 85% one-off (APAG gain plus deferred-tax credit), and Q1FY27 includes a ₹6.3 Cr NCRPS gain. Continuing-operations profit before the gain was modest, and the Q1FY27 revenue surge is unexplained in disclosures. It may reflect transient price pass-through rather than structural gains (margin expanded only from 9.0% to about 11%).
-
Cyclicality and dumping. Standalone operating margin fell from 9% (FY22) to 1% (FY24) within two years. Management itself flags Chinese, Gulf and Russian dumping, US tariffs on hexamine and raw-material volatility.
-
Governance and disclosure discount. CMD duality, 29.6% promoter pledge, related-party APAG co-shareholder, FY26 filing-delay observations, about ₹178 Cr contingent liabilities, negligible institutional ownership, no earnings calls and no R&D or capacity disclosure.
Key catalysts and monitorables (next 12 months)
-
Q2FY27 results (due around November 2026): does revenue stay above ₹400 Cr a quarter, and does EBITDA margin hold above 9.5%?
-
Commissioning dates and early utilisation of the Triacetin and multi-purpose Penta-derivative plants.
-
Methanol and phenol price trajectory, and any reversal of Q1FY27 realisations.
-
Penta import volumes and any DGTR action on hexamine or sodium formate.
-
US tariff developments affecting hexamine exports.
-
KAT weaving-expansion decision and Birr stability.
-
CARE rating action.
-
Changes in promoter pledge.
-
NCRPS accounting (fair-value movements through P&L).
-
Status of the KAT 13.79% stake sale.
-
Gujarat environmental compliance at Ankleshwar.
Analyst verdict
Kanoria Chemicals & Industries is at a genuine inflection point, but the reported numbers overstate the change. Strip away the ₹97.65 Cr non-cash gain on APAG and the ₹21.4 Cr deferred-tax credit, and FY26 was a recovery year rather than a breakout. The core chemicals franchise raised EBITDA to ₹81.6 Cr at a 9.3% margin, and the Ethiopian denim unit returned to positive EBITDA. Exiting APAG was strategically correct: it removed a structurally challenged, sub-scale European automotive-electronics business that was absorbing capital and management attention. It also halved consolidated debt and leaves a small residual option (14.3%, to be sold in FY2029-30).
What makes the equity story newly interesting is Q1FY27. Standalone revenue of ₹430 Cr in a single quarter is almost half of FY26's total, and the market has reacted (+128% over one year). The company has not explained the scale of this jump. With capacity broadly unchanged and margins up only modestly, investors should assume a meaningful price or pass-through component until proven otherwise. If even two-thirds of the Q1 run-rate persists and the Triacetin and Penta-derivative plants start on schedule, the stock at about 9x trailing EV/EBITDA would still look undemanding for an integrated formaldehyde-chain leader with trade protection on its flagship Penta.
The discount has identifiable causes: commodity cyclicality, dumping exposure, a BB+ balance sheet, promoter-dominated governance with a 29.6% pledge, and thin disclosure (no guidance, no calls, no R&D or capacity-by-product data). Our stance is constructive but evidence-contingent. Q2 and Q3 FY27 prints showing sustained revenue above ₹400 Cr a quarter at double-digit EBITDA margins, specialty-plant commissioning, and a reduced pledge would together justify a re-rating. Any reversion toward the FY26 quarterly run-rate (₹250–300 Cr) would expose the current price as anticipating more than the business has yet proven.
APPENDIX: SOURCES
-
Kanoria Chemicals & Industries, FY2025-26 (66th) Annual Report, Directors' Report (via IndiaInfoline): https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd/reports/directors-report
-
Kanoria Chemicals & Industries, FY2024-25 Management Discussion & Analysis (via IndiaInfoline): https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd/management-discussions/743
-
NSE filing: APAG dilution/divestment outcome, 29 Jul 2025: https://a.storyblok.com/f/209886/x/1ae52b60d4/outcome_-dilution-and-divestment-of-equity-stake-in-apag-holding-ag-switzerland-a-meterial-subsidiary-company.pdf
-
NSE filing: APAG shareholders' agreement, 16 Sep 2025: https://nsearchives.nseindia.com/corporate/KANORICHEM_16092025182440_Letter.pdf
-
NSE filing: GPCB closure order, 21 Sep 2024: https://nsearchives.nseindia.com/corporate/KANORICHEM_21092024175803_Pollution_control_board_complaint.pdf
-
NSE filing: GPCB order revoked, 9 Oct 2024: https://nsearchives.nseindia.com/corporate/KANORICHEM_09102024165419_Letter.pdf
-
NSE filing: KAT share disposal, 28 Jan 2025: https://nsearchives.nseindia.com/corporate/KCIL2024_28012025123319_Intimation2801.pdf
-
NSE filing: Q3FY25 results, 13 Feb 2025: https://nsearchives.nseindia.com/corporate/KANORICHEM_13022025161945_Result.pdf
-
NSE filing: Q2FY26 results, 10 Nov 2025: https://nsearchives.nseindia.com/corporate/KANORICHEM_10112025194519_Results.pdf
-
NSE filing: FY26 results newspaper publication, 26 May 2026: https://nsearchives.nseindia.com/corporate/KANORICHEM_26052026160322_Letter.pdf
-
BSE filing: Supreme Court order disclosure, 30 Jan 2026: https://bsmedia.business-standard.com/_media/bs/data/announcements/bse/30012026/9be2120e-febe-48a1-b5b9-f8ae3eb876e7.pdf
-
BSE filing: Supreme Court clarification, 2 Feb 2026: https://bsmedia.business-standard.com/_media/bs/data/announcements/bse/02022026/73e8fd03-a5a7-4b7a-ba6f-f5473fc254ca.pdf
-
BSE filing: COVID-19 suspension, 25 Mar 2020: https://bseindia.com/xml-data/corpfiling/AttachHis/0116cea5-732c-42b8-9312-b995ce204de4.pdf
-
BSE filing: BRSR FY2022-23: https://bseindia.com/xml-data/corpfiling/AttachHis/68c7e9a3-bdcb-4f8a-ab6d-01b3e9b8cd5a.pdf
-
Screener.in, standalone: https://www.screener.in/company/506525/
-
Screener.in, consolidated: https://www.screener.in/company/KANORICHEM/consolidated/
-
Anand Rathi, financial results: https://anandrathi.com/stocks/kanoria-chem-inds/financial-results/106525
-
Fyers, P&L: https://fyers.in/stocks/kanoria-chemicals-industries-ltd/profit-loss
-
MarketsMojo, annual results: https://marketsmojo.motilaloswal.com/stocks-analysis/financial-annual/kanoria-chem-611963-0
-
Tickertape: https://www.tickertape.in/stocks/kanoria-chemicals-and-industries-KNRC
-
Kotak Securities / Kotak Neo, Q1FY26 results: https://www.kotakneo.com/financial-results/kanoria-chemicals-industries-ltd-q1fy2025-26-results
-
Simply Wall St, FY2025 earnings: https://simplywall.st/stocks/in/materials/nse-kanorichem/kanoria-chemicals-industries-shares/news/kanoria-chemicals-industries-full-year-2025-earnings-1934-lo/amp
-
ScanX, news hub: https://scanx.trade/stock-news/kanoria-chemicals-industries-ltd
-
ScanX, Q1FY27 results: https://scanx.trade/stock-market-news/companies/kanoria-chemicals-q1-results-net-profit-surges-673-yoy-to-264-crore/47987120
-
ScanX, 66th AGM / FY26: https://scanx.trade/stock-market-news/companies/kanoria-chemicals-industries-concludes-66th-agm-shareholder-approval/49896550
-
Multibagg, Q1FY27: https://www.multibagg.ai/market-pulse/articles/kanoria-chemicals-q1fy27-results-profit-cmspzww2h0v010znx92zvm986
-
IndiaInfoline, shareholding: https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd/share-holding
-
IndiaInfoline, company summary / history: https://www.indiainfoline.com/company/kanoria-chemicals-industries-ltd-share-price-management/summary/743
-
EnrichMoney, company milestones: https://enrichmoney.in/orca/stock-analysis/kanoria-chem-inds-company-details
-
InvestYadnya, company profile: https://investyadnya.in/stock-o-meter/kanoria-chemicals-&-industries
-
Goodreturns, company history: https://www.goodreturns.in/company/kanoria-chemicals-industries/history.html
-
Walder Wyss, APAG acquisition (2012): https://walderwyss.com/de/news/2012-05-08_kanoria-chemicals-industries-ltd-acquires-apag-holding-ag
-
Machinist, APAG transaction: https://machinist.in/2025/07/anevolve-asia-investments-uk-to-acquire-majority-stake-in-apag-from-kanoria-chemicals/
-
Maritime Gateway / Business Line, Penta anti-dumping duty: https://www.maritimegateway.com/india-imposes-anti-dumping-duty-on-pentaerythritol-imports-from-china-saudi-arabia-and-taiwan
-
Polymers Paint Colour Journal, Penta investigation: https://www.polymerspaintcolourjournal.com/?p=15289
-
Global Trade Alert, Penta anti-dumping duty: https://globaltradealert.org/state-act/75478-india-definitive-antidumping-duty-on-imports-of-pentaerythritol-from-china-saudi-arabia-and-chinese-taipei
-
Zerodha / Reuters briefs (solar sale; Penta leadership): https://zerodha.com/markets/stocks/NSE/KANORICHEM/
-
TipRanks, ratios (used only for cash-ratio indication): https://www.tipranks.com/stocks/in:kanorichem/financials/ratios
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Committees | Tenure / notes |
|---|---|---|---|---|
Rajya Vardhan (R.V.) Kanoria | Chairman & Managing Director | Executive, Promoter | Audit (member), NRC (member), CSR (member), Risk Management (Chairman), Committee of Directors (Chairman) | — |
Saumya Vardhan (S.V.) Kanoria (DIN 02097441) | Whole-Time Director | Executive, Promoter | Stakeholders' Relationship, Risk Management, Committee of Directors | Re-appointed for 3 years from 1 Apr 2025; aged about 42 (Feb 2025 disclosure); son of R.V. Kanoria |
Madhuvanti Kanoria | Director | Non-Executive, Non-Independent (Promoter) | CSR (Chairperson) | Related to R.V. and S.V. Kanoria per Feb 2025 relationship disclosure |
Hemant Kumar Khaitan (DIN 00220049) | Director | Non-Executive, Non-Independent | Stakeholders' Relationship, Committee of Directors | Appointed 4 Sep 2024; re-appointed on rotation at 66th AGM |
Meeta Makhan | Director | Independent | Audit (Chairperson), NRC, CSR, Committee of Directors | — |
Sidharth Kumar Birla | Director | Independent | NRC (Chairman), Audit, Risk Management | — |
Suhana Murshed (DIN 08572394) | Director | Independent | Stakeholders' Relationship (Chairperson), Audit, Committee of Directors | First term 29 Jun 2021–28 Jun 2026; re-appointed for 5 years from 29 Jun 2026 (special resolution, 66th AGM) |
Sumanta Chaudhuri | Director | Independent | Audit (from 10 Nov 2025), NRC | — |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
R.V. Kanoria | CMD | — |
S.V. Kanoria | Whole-Time Director | — |
Nirmal Kumar (N.K.) Nolkha | Group Chief Financial Officer | Member, Risk Management Committee |
Pratibha Jaiswal | Company Secretary & Compliance Officer | Succeeded Neha Saraf (CS as of Oct 2024); no KMP change in FY26 |
Governance Overview
| Metric | Value |
|---|---|
Board size | 8 |
Independent directors | 4 (50%), meeting the SEBI LODR requirement for an executive-promoter chair |
Women directors | 3 (37.5%) |
Chair/CEO separation | No. The Chairman is also Managing Director and promoter |
Board meetings FY26 | 5 |
Audit Committee meetings FY26 | 4 |
Auditor opinion FY26 | Unqualified (statutory and secretarial) |
Annual Secretarial Compliance Report FY26 | Notes filing delays and minor compliance observations (filed 29 May 2026) |
Shareholding Trend
| Holder category (%) | Jun-2025 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|
Promoters, Indian | 73.40 | 73.40 | 73.40 | 73.40 | 73.40 |
Promoters, Foreign | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
Institutions | 0.12 | 0.11 | 0.07 | 0.11 | 0.12 |
Non-institutions (retail, corporates, others) | 25.47 | 25.48 | 25.52 | 25.48 | 25.48 |
Competitive Landscape
Competitors by Segment
| Product line | Named competitors | Positioning vs KCIL |
|---|---|---|
Pentaerythritol (India) | Asian Paints (captive/merchant Penta producer; DGTR names KCIL and Asian Paints as the two major domestic producers); importers of Chinese, Saudi and Taiwanese Penta (subject to anti-dumping duty from May 2024) | KCIL described by Reuters as India's top Penta producer; protected by anti-dumping duty |
Pentaerythritol (global) | Perstorp (Sweden), Ercros (Spain), Hubei Yihua and other Chinese producers, Chang Chun Group (Taiwan) | Global scale players; KCIL is sub-scale globally |
Formaldehyde | Regional Indian producers and captive producers at resin, plywood and laminate makers (e.g., Hexion/Bakelite Synthetics lineage in resins) | KCIL at about 1,400 TPD across three sites claims scale and technology cost advantage; formaldehyde is non-tradable over long distances, favouring a multi-site footprint |
Hexamine | Chinese exporters; Indian producers | KCIL exports a significant share; threatened by cheaper imports and US tariffs |
Sodium formate | Chinese/imported product | Management cites cheaper imports as a threat |
Phenolic resins | Hexion/Bakelite Synthetics, SI Group, Sumitomo Bakelite, Prefere Resins, domestic resin makers | KCIL is a smaller, integrated (captive formaldehyde) player |
Denim (Ethiopia) | Other Ethiopian/East African textile mills and Asian imports | KAT cites "intensifying competition in the local market" |
Competitor Detail
| Metric | KCIL (FY26) |
|---|---|
Revenue | ₹981 Cr consolidated / ₹875 Cr standalone |
Revenue growth | +30% (continuing basis) |
EBITDA margin | 9.6% consolidated / 9.3% standalone |
Recent Developments
20 Sep 2024: GPCB closure order on Ankleshwar.
9–10 Oct 2024: order revoked and operations resumed.
13 Feb 2025: Q3FY25 results, with an exceptional impairment based on external valuation.



